Gossamer Bio Inc. (NASDAQ: GOSS)
$1.24
+0.0600 ( +5.08% ) 4.3M
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Market Data
Open
$1.24
Previous close
$1.18
Volume
4.3M
Market cap
$282.77M
Day range
$1.18 - $1.33
52 week range
$0.45 - $1.88
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 25, 2024 |
4 | Insider transactions | 1 | Jun 24, 2024 |
4 | Insider transactions | 1 | Jun 20, 2024 |
4 | Insider transactions | 1 | Jun 20, 2024 |
8-k | 8K-related | 13 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
8-k | 8K-related | 13 | May 24, 2024 |